Two classes of anti-viral agents, the M2 ion channel inhibitors (amantadine, rimantadine) and neuraminidase (NA) inhibitors (oseltamivir, zanamivir) are available for treatment and prevention of infl uenza in most countries of the world. The principle concerns about emergence of antiviral resistance in infl uenza viruses are loss of drug effi cacy, transmission of resistant variants, and possible increased virulence or transmissibility of resistant variants (1). Because seasonal infl uenza is usually an acute, self-limited illness in which viral clearance occurs rapidly due to innate and adaptive host immune responses, the emergence of drug-resistant variants would be anticipated to have modest effects on clinical recovery, except perhaps in immunocompromised or immunologically naïve hosts, such as young infants or during the appearance of a novel strain. In contrast to the limited impact of resistance emergence in the treated immunocompetent individual, the epidemiologic impact of resistance emergence and transmission could be considerable, including loss of both prophylactic and therapeutic activity for a particular drug, at the household, community, or perhaps global level. Infl uenza epidemiology in temperate climates is expected to provide some protection against widespread circulation of resistant variants, as viruses do not persist between epidemics but rather are re-introduced each season and new variants appear often (2, 3).
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Hayden FG, Monto AS, Webster R, Zambon M. NISN Statement on antiviral resistance in influenza viruses. Weekly Epidemiological Record 2004; 79(33):306–308
Russell CA, Jones TC, Barr IG et al. The global circulation of seasonal influenza A (H3N2) viruses. science 2008; 320(5874):340–346
Rambaut A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK, Holmes EC. The genomic and epidemiological dynamics of human influenza A virus. Nature 2008; 453:615–619
Bright RA, Medina Mj, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. The Lancet 2005; 366:1175–1181
Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA: The Journal of American Medical Association-Express (online) (doi:10.1001/jama.295.8.joc60020), 295. 2-2-2006.
WHO/ECDC. WHO/ECDC Frequently Asked Questions for Oseltamivir Resistance. http://www.who.int/csr/disease/influenza/ oseltamivir_faqs/en/index.html. 2008.
6a. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Current Opinion in Infectious Diseases 2008, 21:626–638
WHO Departmentof Communicable Disease Surveillance and Response. WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics. 2004. http://www.who.int/csr/ resources/publications/influenza/WHO_CDS_CSR_RMD_2004_8
Hayden FG. Antiviral resistance in influenza viruses — implications for management and pandemic response. The New England Journal of Medicine 2006; 354(8):785–788
Cochran KW, Maassab HF, Tsunoda A, Berlin BS. Studies on the antiviral activity of amantadine hydrochloride. Annals of the New York Academy of Sciences 1965; 130:432–43910.
Oxford JS, Logan IS. In vivo selection of an influenza A2 strain resistant to amantadine. Nature 1970; 226:82–83
Hay AJ. Amantadine and rimantadine — mechanisms. In: Richman DD, editor. Antiviral Drug Resistance. Chichester, England: John Wiley & Sons Ltd, 1996:43–58
Hall CB, Dolin R, Gala CL et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987; 80(2):275–282
Belshe RB, Burk B, Newman F, Cerruti RL, Sim IS. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. Journal of Infectious Diseases 1989; 159(3):430–435
Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. New England Journal of Medicine 1989; 321(25):1696–1702
Mast EE, Harmon MW, Gravenstein S et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991; 134(9):988–997
Hayden FG. Amantadine and rimantadine — clinical aspects. In: Richman DD, editor. Antiviral Drug Resistance. Chichester, England: John Wiley & Sons Ltd, 1996:59–77
Saito R, Oshitani H, Masuda H, Suzuki H. Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-Restriction fragment length polymorphism analysis with nasopharyngeal swabs. Journal of Clinical Microbiology 2002; 40:84–88
Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. Journal of Infectious Diseases 2003; 188:57–61
Saito R, Sakai T, Sato I et al. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. Journal of Clinical Microbiology 2003; 41(5):2164–2165
Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. Journal of Virology 1991; 65(10):5491–5498
Tumpey TM, Garcia-Sastre A, Mikulasova A et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proceedings of the National Academy of Sciences of the United States of America 2002; 99(21):13849–13854
Ziegler T, Hemphill ML, Ziegler ML et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. Journal of Infectious Diseases 1999; 180(4):935–939
Dawson J. Neuraminidase inhibitor and amantadine. Lancet 2000; 355:2254
Suzuki H, Saito R, Oshitani H. Excess amantadine use and resistant viruses. Lancet 2001; 358:1910
Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N. Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use. Archives of Internal Medicine 1995; 155(5):533–537
Simonsen L, Viboud C, Grenfell BT et al. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Molecular Biology and Evolution 2007; 24(8):1811–1820
Barr IG, Hurt AC, Iannello P, Tomasov C, Deed N, Komadina N. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. Antiviral Research 2007; 73(2):112–117
Deyde VM, Xu X, Bright RA et al. Surveillance of Resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. The Journal of Infectious Diseases 2007; 196(2):249–257
Deyde V, Garten R, Sheu T, Gubareva L, Klimov A. Reply to Saito et al. The Journal of Infectious Diseases 2008; 197(4):632–633
Schmidtke M, Zell R, Bauer K et al. Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. Intervirology 2006; 49(5):286–293
Marozin S, Gregory V, Cameron K et al. Antigenic and genetic diversity among swine influenza A H1N1 and H1N2 viruses in Europe. Journal of General Virology 2002; 83(Pt 4):735–745
31a. Olsen CW, Karasin AI, Carman S, Li YCW, et al. Triple reas-sortant H3N2 influenza A viruses, Canada, 2005. Emerging Infectious Diseases 2006; 12(7):1132–1135.
Gregory V, Lim W, Cameron K et al. Infection of a child in Hong Kong by an influenza A H3N2 virus closely related to viruses circulating in European pigs. Journal of General Virology 2001; 82:1397–1406
Ilyushina NA, Govorkova EA, Webster RG. Detection of amanta-dine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology 2005; 341:102–106.
He G, Qiao J, Dong C, He C, Zhao L, Tian Y. Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Research 2008; 77(1):72–76
34a. Ilyushina NA, Govorkova EA, Russell CJ, Hoffmann E, Webster RG. Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus. Journal of General Virology 2007; 88:1266–1274.
34b. Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Current Concepts: Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374–1385.
Hien TT, Liem NT, Dung NT et al. Avian influenza A (H5N1) in 10 patients in Vietnam. New England Journal of Medicine 2004; 350(12):1179–1188
Peiris JS, Yu WC, Leung CW et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363:617–619
Cheung CL, Rayner JM, Smith GJD et al. Distribution of amanta-dine-resistant H5N1 avian influenza variants in Asia. The Journal of Infectious Diseases 2006; 193(12):1626–1629
Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Research 2007; 73(3):228–231
Bean WJ, Threlkeld SC, Webster RG. Biologic potential of amantadine-resistant influenza A virus in an avian model. Journal of Infectious Diseases 1989; 159(6):1050–1056
Herlocher ML, Truscon R, Fenton R et al. Assessment of development of resistance to antivirals in the ferret model of influenza virus infection. Journal of Infect Diseases 2003; 188:1355–1361
Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrobial Agents & Chemotherapy 1991; 35(9):1741–1747
Englund JA, Champlin RE, Wyde PR et al. Common emergence of amantadine and rimantadine resistant influenza A viruses in symptomatic immunocompromised adults. Clinical Infectious Disease 1998; 26(6):1418–1424
Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. Journal of Infectious Diseases 1995; 172(5):1352–1355
Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza A virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clinical Infectious Disease 2002; 34:e23–e25
Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompro-mised patient. New England Journal of Medicine 2003; 348(9):867–868
La Rosa AM, Malik S, Englund JA et al. Influenza A in hospitalized adults with leukemia and hematopoietic stem call transplant (HSCT) recipients; risk factors for progression to pneumonia. Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, October 25–28, 2001, 111, Abstract #418
Lee C, Loeb M, Phillips A et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infection Control & Hospital Epidemiology 2000; 21(11):700–704
Tamblyn SE. Antiviral use during influenza outbreaks in long-term care facilities. In: Osterhaus A, Cox N, Hampson A, editors. Options for the Control of Influenza I V. New York: Excerpta Medica, 2001:817–822
Pohani G, Henry B, Nsubuga J. Summary report of the 1999/00 Ontario influenza season. Public Health and Epidemiology Report Ontario 2000; 11(7):136–154
Bowles SK, Lee W, Simor AE et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999–2000. Journal of American Geriatrics Society 2002; 50:608–616
Drinka PJ, Haupt T. Emergence of rimantadine-resistant virus within 6 days of starting rimantadine prophylaxis with oseltami-vir treatment of symptomatic cases. Journal of the American Geriatrics Society 2007; 55(6):923–926
Hirji Z, O'Grady S, Bonham J et al. Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing-care population. Canada Communicable Disease Report 2001; 27(3):21–24
Gravenstein SMMC, Drinka PM, Osterweil DM et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. Journal of the American Medical Directors Association 2005; 6(6):359–366
Iwahashi J, Tsuji K, Ishibashi T et al. Isolation of amantadine-resistant influenza A viruses (H3N2) from patients following administration of amantadine in Japan. Journal of Clinical Microbiology 2001; 39(4):1652–1653
Kawai N, Ikematsu H, Iwaki N, Kawamura K, Kawashima T, Kashiwagi S. A change in the effectiveness of amantadine for the treatment of influenza over the 2003–2004, 2004–2005, and 2005–2006 influenza seasons in Japan. Journal of Infection and Chemotherapy 2007; 13(5):314–319
Degelau J, Somani SK, Cooper SL, Guay DR, Crossley KB. Amantadine-resistant influenza A in a nursing facility. Archives of Internal Medicine 1992; 152(2):390–392
Rahman M, Bright RA, Kieke BA et al. Adamantane-resistant influenza infection during the 2004–05 season. Emerging Infectious Diseases 14(1):173–6, 2008
Sweet C, Hayden FG, Jakeman KJ, Grambas S, Hay AJ. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. Journal of Infectious Diseases 1991; 164(5):969–972
Watanabe T, Watanabe S, Ito H, Kida H, Kawaoka Y. Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity. Journal of Virology 75(12):5656–62, 2001
Abed Y, Goyette N, Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrobial Agents & Chemotherapy 2005; 49(2):556–559
Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Research 2006; 70(3):121–131
Ison MG, Gnann JW Jr, Nagy-Agren S et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antiviral Therapy 2003; 8:183–190
Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Current Concepts: Update on Avian Influenza A (H5N1) Virus Infection in Humans. N Engl J Med 2008;358:261–73.
63a. Ilyushina NA. Hoffmann E, Salomon R, Webster RG, Govorkova EA. Amantadine-oseltamivir combination therapy for H5N1 influenza infection in mice. Antiviral Ther 2007; 12:263–370.
Knight V, Gilbert BE. Ribavirin aerosol treatment of influenza. [Review]. Infectious Disease Clinics of North America 1987; 1(2):441–457
Smith CB, Charette RP, Fox JP, Cooney MK, Hall CE. Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. Journal of Infectious Diseases 1980; 141(5):548–554
Stein DS, Creticos CM, Jackson GG et al. Oral ribavirin treatment of influenza A and B. Antimicrobial Agents & Chemotherapy 1987; 31(8):1285–1287
Hayden FG, Sable CA, Connor JD, Lane. Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection. Antiviral Therapy 1996; 1(1):51–56
De Clercq E. Antiviral agents active against influenza A viruses. Nature Reviews: Drug Discovery 2006; 5(12):1015–1025
Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Research 2008; 78(1):91–102
69a. Hayden F. Developing new antiviral agents for influenza treatment: What does the future hold? Clin Infect Dis 2009; 48:S3–S13.
McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors — a review. Antiviral Research 2000; 47:1–17
Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Reviews in Medical Virology 2000; 10:45–55
Zambon M, Hayden FG. Position statement: global neurami-nidase inhibitor susceptibility network. Antiviral Research 2001; 49:147–156
McKimm-Breschkin JL. Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opinion on Pharmacotherapy 2002; 3(2):103–112
Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Research 2002; 54(3):143–147
Hurt AC, Barr IG, Hartel G, Hampson AW. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Research 2004; 62(1):37–45
Sugaya N, Mitamura K, Yamazaki M et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clinical Infectious Disease 2007; 44(2):197–202
Kawai N, Ikematsu H, Iwaki N et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002–2003 influenza season. Clinical Infectious Disease 2005; 40(9):1309–1316
Kawai N, Ikematsu H, Iwaki N et al. Zanamivir treatment is equally effective for both influenza A and influenza B. Clinical Infectious Disease 2007; 44(12):1666
NISN. Use of influenza antivirals during 2003–2004 and monitoring of neuraminidase inhibitor resistance. Weekly Epidemiological Record 2005; 80(17):156
Monto AS, Kimm-Breschkin JL, Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrobial Agents & Chemotherapy 50(7):2395–402, 2006
Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. Journal of Virology 2003; 77(15):8418–8425
Hatakeyama S, Sakai-Tagawa Y, Kiso M et al. Enhanced expression of an {alpha}2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. Journal of Clinical Microbiology 2005; 43(8):4139–4146
Yen HL, Herlocher LM, Hoffmann E et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrobial Agents & Chemotherapy 2005; 49(10):4075–4084
Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Research 2004; 103(1–2):199–203
Abed Y, Bourgault AM, Fenton RJ et al. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. Journal of Infectious Diseases 2002; 186(8):1074–1080
85a. Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, Webster RG. Human-like receptor specificity does not affect the neurami-nidase inhibitor susceptibility of H5N1 influenza viruses. PLoS Pathogens 2008; 4(4):e1000043.
Chutinimitkul S, Suwannakarn K, Chieochansin T et al. H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes. Journal of Virological Methods 2007; 139(1):44–49
86a. Carr MJ, Sayre N, Duffy M, Connell J, Hall WW. Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses. Journal of Virological Methods 2008;153:257–262.
Wetherall NT, Trivedi T, Zeller J et al. Evaluation of neurami-nidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. Journal of Clinical Microbiology 2003; 41(2):742–750
Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at his274 alter sensitivity of influenza a virus N1 neurami-nidase to oseltamivir carboxylate and zanamivir. Antimicrobial Agents & Chemotherapy 2002; 46(12):3809–3816
Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrobial Agents & Chemotherapy 2005; 49(11):4515–4520
Gubareva LV, McCullers JA, Bethell RC, Webster RG. Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. Journal of Infectious Diseases 1998; 178(6):1592–1596
Leneva IA, Goloubeva O, Fenton RJ, Tisdale M, Webster RG. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrobial Agents & Chemotherapy 2001; 45(4):1216–1224
Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrobial Agents & Chemotherapy 2001; 45(10):2723–2732
Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. British Medical Journal 2003; 326(7401):1235–1239
McKimm-Breschkin J, Trivedi T, Hampson A et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrobial Agents & Chemotherapy 2003; 47(7):2264–2272
Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antiviral Therapy 2007; 12(4 Pt B):603–616
Hurt AC, Iannello P, Jachno K et al. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrobial Agents & Chemotherapy 2006; 50(5):1872–1874
Hurt AC, McKimm-Breschkin JL, McDonald M, Barr IG, Komadina N, Hampson AW. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs. Virus Research 2004; 103(1–2):205–211
Mungall BA, Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000–2002 influenza seasons. Virus Research 2004; 103(1–2):195–197
Ferraris O, Kessler N, Valette M, Lina B. Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005. Vaccine 2006; 24(44–46):6656–6659
99a. Escuret V, Frobert E, Bouscambert-Duchamp M, Sabatier M, et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. Journal of Clinical Virology 2008; 41:25–28.
Hatakeyama S, Sugaya N, Ito M et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase Inhibitors. JAMA: The Journal of the American Medical Association 2007; 297(13):1435–1442
Lackenby A, Baldevarona J, Democratis J et al. Decreasing sensitivity of influenza B viruses. Abstract Book — Options for the Control of Influenza VI, Toronto, ON, Canada, June 17–23, 2007, 238, Abstract #P930
Neuraminindase Inhibitor Susceptibility Network. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003–2006 influenza seasons. Weekly Epidemiological Record 2007; 82(17):149–150
Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrobial Agents & Chemotherapy 2001; 45(12):3403–3408
Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antiviral Therapy 2006; 11(8):971–976
104a. van der Vries E, van den Berg B, Schutten M. Fatal oseltami-vir-resistant influenza virus infection. N Engl J Med 2008; 359(10):1074–1076.
World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir. http://www.who.int/csr/disease/influenza/ h1n1_table/en/index.html. 2008. http://www.who.int/csr/disease/ influenza/h1n1_table/en/print.html
105a. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir, last quarter 2007 to first quarter 2008, Preliminary summary and future plans. 2008. http://www.who. int/csr/disease/influenza/oseltamivir_summary/en/index.html
Hurt AC, Barr IG. Novel mutations in the ‘150-cavity’ of N1 neu-raminidase confer reduced sensitivity to the neuraminidase inhibitors. Abstract Book — Options for the Control of Influenza VI, Toronto, ON, Canada, June 17–23, 2007, 48 Abstract #067, 2008
Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Research 73(3):228–31, 2007
Yatsyshina S, Shestopalov A, Evseyenko V et al. Isolation and molecular characterization of the influenza A/H5N1 viruses isolated during the outbreaks of avian influenza among birds in the European part of Russia in 2005: a virus strain with ozeltamivir-resistance mutation was found. Molecular Genetics, Microbiology and Virology 2008; 23(1):31–41
Rayner JM, Cheung CL, Smith GJD et al. Naturally occurring antiviral drug resistance in avian H5N1 virus. Abstract Book — Options for the Control of Influenza VI, Toronto, ON, Canada, June 17–23, 2007, 48 Abstract #068
109a. Yen HL, Lipatov AS, Ilyushina NA, Govorkova EA, Franks J, Yilmaz N, et al. Inefficient transmission of H5N1 influenza viruses in a ferret contact model. J Virol 2007 81(13):6890–6398.
Saad MD, Boynton BR, Earhart KC et al. Detection of osel-tamivir resistance mutation N2945S in humans with influenza A H5N1. Abstract Book — Options for the Control of Influenza VI, Toronto, ON, Canada, June 17–23, 2007, 228 Abstract # P909
Rameix-Welti MA, Agou F, Buchy P et al. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrobial Agents & Chemotherapy 2006; 50(11):3809–3815
Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 (H5N1) influenza virus in mice. Journal of Infectious Diseases 2005; 192(4):665–672
McKimm-Breschkin J, Selleck P, Usman TB, Johnson M. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerging Infectious Diseases 2007; 13(9):1354–1357
113a. Le MTQ, Wertheim HFL, Nguyen HD, Taylor W, et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in Northern Vietnam. PLoS ONE 2008; 3(10):e3339.
Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrobial Agents & Chemotherapy 2007; 51(4):1414–1424
114a. Ilyushina NA, Hay A, Yilmaz N, Boon ACM, Webster RG, Govorkova EA. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus Infection in mice. Antimicrobial Agents Chemother 2008; 52(11):3889–3897.
114b. Boltz DA, Rehg JE, McClaren J, Webster RG, Govorkova EA. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. Journal of Infectious Diseases 2008; 197:1315–1323
Thompson CI, Barclay WS, Zambon MC. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. Journal of Antimicrobial Chemotherapy 2004; 53(5):759–765
Barnett J, Cadman A, Gor D et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrobial Agents & Chemotherapy 2000; 44(1):78–87
Jackson HC, Roberts N, Wang Z, Belshe R. Management of influenza Use of new antivirals and resistance in perspective. Clinical Drug Investigation 2000; 20(6):447–454
Roberts N. Treatment of influenza with neuraminidase inhibitors: virological implications. Philosophical Transactions of the Royal Society 2001; 356(1416):1895–1897
Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. Journal of Infectious Diseases 2001; 183:523–531
Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437(7062):1108
Menno D. de Jong MD, Thanh TT, Khanh TH, Hien VM, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667–2672.
Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu(R)) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55(Suppl_1):i5–21
Whitley RJ, Hayden FG, Reisinger K et al. Oral oseltamivir treatment of influenza in children. Pediatric Infectious Disease Journal 2001; 20(2):127–133
Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364(9436):759–765
Democratis J, Lakenby A, McNally T et al. A prospective study to assess the emergence and transmissibility of resistance to osel-tamivir following treatment of children with influenza. Abstract Book — Options for the Control of Influenza VI, Toronto, ON, Canada, June 17–23, 2007, 228, Abstract # P923
Gubareva LV, Matrosovich MN, Brenner MK, Bethell R, Webster RG. Evidence for zanamivir resistance in an immuno-compromised child infected with influenza B virus. Journal of Infectious Diseases 1998; 178(5):1257–1262
Ison MG, Hayden FG, Mishin V, Braciale TJ, Gubareva L. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. Journal of Infect Diseases 2006; 193:765–772
Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clinical Infectious Disease 2006; 43(12):1555–1561
Machado CM, Boas L, Mendes A et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplantation 2004; 34(2):111–114
129a. Chemaly RF, Torres HA, Aguilera EA, Mattiuzzi G, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 2007; 44:964–967.
129b. Ison MG, Mishin VP, Braciale TJ, Hayden FG, Gubareva LV. Comparative activities of oseltamivir and A-322278 in immuno-competent and immunocompromised murine models of influenza virus infection. Journal of Infectious Diseases 2006; 193:765–72
Johny AA, Clark A, Price N, Carrington D, Oakhill A, Marks DI. The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplantation 2002; 29(2):113–115
Herlocher ML, Carr J, Ives J et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Research 2002; 54(2):99–111
Herlocher ML, Truscon R, Elias S et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. The Journal of Infectious Diseases 2004; 190(9):1627–1630
132a. Bouvier NM, Lowen AC, Palese P. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol 2008; 82(20):10052–10058.
Carr J, Ives J, Kelly L et al. Influenza virus carrying neurami-nidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectiv-ity and replicative ability in vivo. Antiviral Research 2002; 54(2):79–88
Tai CY, Escarpe PA, Sidwell RW et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrobial Agents & Chemotherapy 1998; 42(12):3234–3241
134a. Rameix-Welti M-A, Enouf V, Cuvelier F, Jeannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathogens 2008; 4(7):e1000103
Ives JAL, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltami-vir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Research 2002; 55:307–317
Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. Journal of Virology 2007; 81(22):12418–12426
Mishin VP, Hayden FG, Signorelli KL, Gubareva LV. Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection. Antiviral Research 71(1):64–8, 2006
Gubareva LV. Characterization of influenza A and B viruses recovered from immunocompromised patients treated with antivirals. In: Kawaoka Y, editor. Options for the Control of Influenza V. Amsterdam: Elsevier BV, 2004:126–129
138a. Medeiros R, Rameix-Welti AM, Lorin V, Ribaud P, et al. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antiviral Ther 2007;12:571–576.
Jackson D, Barclay W, Zurcher T. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. The Journal of Antimicrobial Chemotherapy 2005; 55(2):162–169
Calfee DP, Peng AW, Cass L, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrobial Agents & Chemotherapy 1999; 43(7):1616–1620
Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Research 2006; 69(1):39–45
Yun NE, Linde NS, Zacks MA et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008; 374(1):198–209
Makoto Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, and Kubo S. CS-8958, a prodrug of the new neuramini-dase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009; 53(1):186–192
Smee DF, Bailey KW, Morrison A, Sidwell RW. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 2002; 48:88–93
Madren LK, Shipman C Jr, Hayden FG. In vitro inhibitory effects of combinations of anti-influenza agents. Antiviral Chemistry & Chemotherapy 1995; 6(2):109–113
Smee D, Wong MH, Bailey KW, Sidwell RW. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A(H1N1) and B viruses. Antiviral Chemistry & Chemotherapy 2006; 17(4):185–192.
McCaw JM, Wood RG, McCaw CT, McVernon J. Impact of emerging antiviral drug resistance on influenza containment and spread: Influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS ONE 2008; 3(6): e2362
Stilianakis NI, Perelson AS, Hayden FG. Emergence of drug resistance during an influenza epidemic: Insights from a mathematical model. Journal of Infectious Diseases 1998; 177:863–873
Regoes RR, Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006; 312(5772):389–391
Lipsitch M, Cohen T, Murray M, Levin BR. Antiviral resistance and the control of pandemic influenza. PLoS Medicine/Public Library of Science 2007; 4(1):e15
Ferguson NM, Mallett S, Jackson H, Roberts N, Ward P. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. Journal of Antimicrobial Chemotherapy 2003; 51:977–990
Alexander ME, Bowman CS, Feng Z et al. Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proceedings of the Royal Society of London — Series B: Biological Sciences 274(1619):1675–84, 2007
Handel A, Longini IM, Jr., Antia R. Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Computational Biology 2007; 3(12):e240
153a. Moghadas SM, Bowman CS, Ro G, Wu J. Population-wide emergence of antiviral resistance during pandemic influenza. PLoS ONE 2008: 3(3): e1839
WHO. Clinical management of human infection with avian influenza A(H5N1) virus 2007. http://www.who.int/csr/disease/avian_ influenza/guidelines/clinicalmanage07/en/index.html
Furuta Y, Takahashi K, Fukuda Y et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrobial Agents & Chemotherapy 2002; 46(4):977–81
Sidwell RW, Barnard DL, Day CW et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrobial Agents & Chemotherapy 2007; 51(3):845–851
Lu J, Guo Z, Pan X et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respiratory Research 2006; 7:43
Simmons CP, Bernasconi NL, Suguitan AL et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Medicine 2007; 4(5):e178
Hanson B, Boon A, Lim A, Webb A, Ooi E, Webby R. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respiratory Research 2006; 7(1):126
Belser JA, Lu X, Szretter K et al. DAS181, A novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. Journal of Infect Diseases 2007; 196(10):1493–1499
Malakhov MP, Aschenbrenner LM, Smee DF et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrobial Agents & Chemotherapy 2006; 50(4):1470–1479
Valette M, Allard JP, Aymard M, Millet V. Susceptibilities to rimantadine of influenza A/H1N1 and A/H3N2 viruses isolated during the epidemics of 1988 to 1989 and 1989 to 1990. Antimicrobial Agents & Chemotherapy 1993; 37(10):2239–2240
Shih S, Lee C, Tsai H, Chen G, Tsao K. Amantadine-resistant influenza A virus in Taiwan. Journal of Formosa Medical Association 2001; 100(9):608–612
Saito R, Li D, Suzuki H. Amantadine-resistant influenza A (H3N2) virus in Japan, 2005–2006. The New England Journal of Medicine 2007; 356(3):312–313
Saito R, Suzuki Y, Li D et al. Increased incidence of adamantane-resistant influenza A(H1N1) and A(H3N2) viruses during the 2006–2007 influenza season in Japan. The Journal of Infectious Diseases 2008; 197(4):630–632
Galbraith AW, Oxford JS, Schild GC, Watson GI. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study. Lancet 1969; 2(629):1026–1028
Bricaire F, Hannoun C, Boissel JP. Prevention of influenza A: Effectiveness and tolerance of rimantadine hydrochloride. La Presse Medicale 1990; 19(2):69–72.
Monto AS, Pichichero ME, Blanckenberg SJ et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. Journal of Infectious Diseases 2002; 186:1582–1588
Welliver R, Monto AS, Carewicz O et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA: The Journal of American Medical Association 2001; 285(6):748–754
Galbraith AW, Oxford JS, Schild GC, Watson GI. Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environ-ment. Bulletin of the World Health Organization 1969; 41(3):677–682
Hayden FG, Gubareva LV, Monto AS et al. Inhaled zanamivir for preventing influenza in families. New England Journal of Medicine 2000; 343(18):1282–1289
Hayden FG, Belshe R, Villanueva C et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without post-exposure prophylaxis. Journal of Infectious Diseases 2004; 189:440–449
Hurt AC, Barr IG. Influenza viruses with reduced sensitivity to the NA inhibitor drugs in untreated young children. Community Drug Intelligence 2008; 32(1):57–62
Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. Journal of Clinical Virology 2008; 41:13–19
Carr J, Ives J, Tai CY et al. An oseltamivir-treatment selected influenza A/Wuhan/359/95 virus with an E119V mutation in the neuraminidase gene has reduced infectivity in vivo. Abstracts of the II International Symposium on Influenza and other Respiratory Viruses, Grand Cayman, Cayman Islands, British West Indies, December 10–12, 1999
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Hayden, F.G. (2009). Antiviral Resistance in Influenza Viruses: Clinical and Epidemiological Aspects. In: Mayers, D.L. (eds) Antimicrobial Drug Resistance. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-60327-595-8_23
Download citation
DOI: https://doi.org/10.1007/978-1-60327-595-8_23
Publisher Name: Humana Press
Print ISBN: 978-1-60327-594-1
Online ISBN: 978-1-60327-595-8
eBook Packages: MedicineMedicine (R0)